Daily-administered lisuride patches (an ergot dopamine agonist) are also under development for both PD and restless legs syndrome, but have not been extensively studied (Prestwick Pharmaceuticals). Small published trials have shown efficacy for both conditions (14,15). A randomized placebo-controlled study of 22 PD patients reported a 50% to 75% decrease in oral medication, reduction of motor fluctuations, improved quality of life, decreased daytime somnolence, and increased duration of nighttime sleep (16). Skin irritation has been reported. To date, no cardiac valvular pathology or other presumed ergotamine adverse events have been reported.
Was this article helpful?